Clinical trials: Liver Inflammation
Acute Hepatitis C
Peginterferon Plus Ribavirin Combination Therapy for Hepatitis C Six Months After Onset of Acute Infection
Patients with acute hepatitis C virus (HCV) infection usually become chronicity if viremia persists after 6 months of infection.
- Trial name
- NCT02377856
- Testing
- pegylated interferon alpha 2a, ribavirin
- Where
- Taiwan
- Volunteers
- 20 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Hepatitis B
Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)
This is a global multi-center, long-term follow-up study to assess durability of efficacy, as measured by maintenance of treatment response from the parent study, in participants who participated in a previous bepirovirsen study…
- Trial name
- B-Sure (NCT04954859)
- Testing
- Bepirovirsen
- Where
- 163 sites in United States, Argentina and 27 more
- Volunteers
- 360 people
- Sponsor
- GlaxoSmithKline
Hepatitis C, Thalassemia
Evaluating the Safety of Two Medications to Treat Hepatitis C in People With Thalassemia (The HepC Study)
Hepatitis C is one of the most common causes of long-term liver disease in the United States. Ribavirin and peginterferon alfa-2a are two medications that are used to treat hepatitis C infection.
- Trial name
- HepC (NCT00502788)
- Testing
- Peginterferon Alfa-2a and Ribavirin, Ribavirin
- Where
- 5 sites in United States, Canada and 1 more
- Volunteers
- 21 people
- Sponsor
- Carelon Research
Hepatitis C Genotype 4
Treatment of Egyptian Hepatitis C Genotype 4 Infected Children and Adolescents With Combined Ledipasvir/Sofosbuvir
This is an open, uncontrolled study of twenty-five chronic HCV infected patients carried out at Yassin Abdel Ghaffar Charity Center for Liver Disease and Research.
- Trial name
- NCT03743727
- Testing
- Combined therapy LDV and SOF
- Where
- Egypt
- Volunteers
- 25 people
- Sponsor
- Yassin Abdelghaffar Charity Center for Liver Disease and Research
Diagnostic, Chronic Viral Hepatitis B
Sysmex-XN 20 Analyser to Assess Lymphocyte Subsets and Other Haematological Parameters in Chronic/Acute Viral Infections
The XN-20, is a full blood count (FBC) analyser with an extended differential counting and flagging System. The XN-Series' individual channels allow real-time reflex analysis, and uses a two stage process to classify the white…
- Conditions
- Diagnostic, Chronic Viral Hepatitis B, Chronic Hepatitis C, Chronic HIV Infection
- Trial name
- SASA (NCT03495570)
- Testing
- blood draw
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- University College, London
Hepatitis, Tuberculosis
Investigation of the Effect of N Acetylcysteine Against Anti-Tuberculosis Drugs Induced Liver Toxicity
Tuberculosis is one of the major health problems in developing countries. Isoniazid, rifampin and pyrazinamide, the first line drugs used for tuberculosis chemotherapy, are associated with hepatotoxicity.
- Trial name
- NCT00564642
- Testing
- N Acetylcysteine
- Where
- Iran
- Volunteers
- 60 people
- Sponsor
- National Research Institute of Tuberculosis and Lung Disease, Iran
Hepatitis C
Effectiveness Of Daclatasvir-Based Regimens In Patients With Chronic Hepatitis C Infection In Europe: Experience From Named Patient Program And From Early Post-Marketing Authorization Period
Using European data from patients included in the Named Patient Program (NPP) and from the early post-marketing authorization period, the present study aims to describe patient characteristics and to describe the effectiveness of…
- Trial name
- NCT02531269
- Where
- Switzerland
- Volunteers
- 249 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis C Virus Infection, Past or Present, Chronic Hepatitis c
Cross Sectional Survey on the Burden, Impacts and Causes of Hepatitis C Virus (HCV) Outbreak in South West Region in Burkina Faso
This study investigates hepatitis C virus (HCV) outbreak in South West general population in Burkina Faso with three specific objectives: estimate HCV prevalence in South West Region general population in 2019; identify factors…
- Trial name
- REVERSO (NCT04136405)
- Where
- Burkina Faso
- Volunteers
- 3,300 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
Hepatocellular Carcinoma, Hepatoma
HepATocellular Cancer Hcv Therapy Study
Subjects with Hepatitis C Virus (HCV) infection, genotype 1 or 4 and with hepatocellular carcinoma (HCC) and a complete response to HCC therapy will be randomised to immediate or delayed (6 months) HCV therapy with Elbasvir…
- Conditions
- Hepatocellular Carcinoma, Hepatoma, Liver Cell Carcinoma, Hepatitis C
- Trial name
- HATCHeT (NCT04546802)
- Testing
- Elbasvir / Grazoprevir Oral Tablet
- Sponsor
- Bayside Health
Hepatitis C
Evaluation of MK-1075 in Participants With Hepatitis C Virus (HCV) Infection (MK-1075-002)
The purpose of this study is to evaluate the safety and pharmacokinetics of MK-1075, and to determine the ability of MK-1075 to reduce HCV viral load, following administration of a single dose in HCV-infected participants.
- Trial name
- NCT02392494
- Testing
- MK-1075
- Volunteers
- 9 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatocellular Carcinoma, HCC
Post Sustained Virological Response (SVR) Hepatocellular Carcinoma (HCC) Screening
Approximately half of the patients receiving treatment for chronic hepatitis C virus (HCV) infection in the United States have advanced liver disease.
- Conditions
- Hepatocellular Carcinoma, HCC, Hepatitis C, HCV
- Trial name
- NCT02833298
- Testing
- Automated reminders, Patient navigation
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
Chronic HCV Hepatitis
Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in G1b Treatment-Naïve, HCV-Infected Patients
Antiviral treatment of G1b Treatment-Naïve HCV-Infected Patients, with non- severe fibrosis, with or without insulin resistance (IR) and/or diabetes mellitus (DM) with EBR/GZR Fixed-Dose Combination for 8 Weeks.
- Trial name
- EGG-18 (NCT03496233)
- Testing
- Elbasvir 50 MG / Grazoprevir 100 MG Oral Tablet [Zepatier]
- Where
- Italy
- Volunteers
- 75 people
- Sponsor
- Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo
Chronic Hepatitis B
Antiviral Efficacy of Switching to ETV Plus TDF
Switching to Entecavir(ETV) plus Tenofovir Disoproxil Fumarate(TDF) combination will result in faster and greater antiviral activity and lower rates of resistance emergence over maintaining…
- Trial name
- NCT01597934
- Testing
- Group A (Zeffix, Sebivo, Hepsera), Group B (Baraclude, Viread)
- Volunteers
- 104 people
- Sponsor
- Yonsei University
Hand, Foot and Mouth Disease
Immunogenicity of the Inactivated EV71 Vaccine Combined With Hepatitis B and Group A Meningococcal Vaccine
The main purpose of this study is to evaluate the immunogenicity and safety of inactivated enterovirus type 71 vaccine combined with recombinant hepatitis B vaccine or Group a meningococcal polysaccharide vaccine.
- Trial name
- NCT06209398
- Testing
- Enterovirus Type 71 Vaccine, inactivated ( Human Diploid Cell ), Recombinant Hepatitis B Vaccine, Group A meningococcal polysaccharide vaccine
- Where
- China
- Volunteers
- 510 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Chronic Hepatitis B
Safety and Efficacy of Adefovir Dipivoxil in Children and Adolescents With Chronic Hepatitis B
The purpose of this study is to investigate the efficacy and safety of adefovir dipivoxil for the treatment of chronic hepatitis B in children and adolescents (age 2 to less than 18 years) following 48 weeks of…
- Trial name
- NCT00095121
- Testing
- Adefovir Dipivoxil (ADV), Lamivudine
- Where
- United States
- Volunteers
- 173 people
- Sponsor
- Gilead Sciences
Hepatitis, Chronic
Telbivudine Versus Lamivudine for Maintenance Therapy of Patients With Chronic Hepatitis B and Negative HBV Viral Load After 6 Month of Treatment With Telbivudine
The aim of this randomized clinical study is to show non-inferiority of a change of anti-viral therapy from telbivudine to lamivudine in patients who have achieved an undetectable viral load at week 24 of telbivudine therapy…
- Trial name
- SASL28 (NCT01005238)
- Testing
- Lamivudine, Telbivudine
- Where
- Switzerland
- Volunteers
- 27 people
- Sponsor
- University Hospital, Basel, Switzerland
Chronic Hepatitis C
A Phase 2a, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C
The purpose of the study is to determine the safety, pharmacokinetics and efficacy of orally administered VX-135 with ribavirin in treatment naive subjects with chronic hepatitis C infection.
- Trial name
- NCT01790100
- Testing
- VX-135, Ribavirin
- Where
- Moldova
- Volunteers
- 20 people
- Sponsor
- Alios Biopharma Inc.
Hepatitis B, Chronic
Predictive Model for Prognosis of Chronic HBV Infection Mothers
Pregnancy is a complex and coordinated physiological process. Pregnancy and the postpartum period are associated with unique changes in the immune system that may impact the natural history of autoimmune diseases and…
- Trial name
- PMFPOEPMWCHI (NCT04805034)
- Testing
- Age, BMI,Baseline HBV DNA, Baseline HBeAg level, Baseline HBsAg level, Antiviral treatment, Serum ALT level
- Where
- China
- Volunteers
- 1,600 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Hepatitis B, Chronic
Study of Therapeutic Vaccination With Intensified Schedule Plus Pegasys Dual Therapy on Chronic Hepatitis B Infection
A randomized, Open label, Single center, Prospective study to compare efficacy and safety of Therapeutic Vaccination with Intensified schedule plus Pegylated Interferon dual Therapy on Seroclearance of Hepatitis B virus Surface…
- Trial name
- E+VIP (NCT02097004)
- Testing
- Peginterferon alfa-2a, HBV vaccination, Entecavir
- Where
- South Korea
- Volunteers
- 111 people
- Sponsor
- Seoul National University Hospital
Hepatitis B, ESRD (End Stage Renal Disease)
Comparing Hepatitis B Vaccination Schedules in Patients on Hemodialysis
People with kidney failure who are on dialysis have a weaker immune response to the hepatitis B vaccine than healthy people. Even after vaccination, many dialysis patients do not develop enough protection against hepatitis B…
- Conditions
- Hepatitis B, ESRD (End Stage Renal Disease), Kidney Failure, Chronic
- Trial name
- 3v4-HEP-DOSE (NCT07784452)
- Testing
- Recombinant Hepatitis B Vaccine - 3-Dose Schedule, Recombinant Hepatitis B Vaccine - 4-Dose Schedule
- Where
- Pakistan
- Volunteers
- 104 people
- Sponsor
- Jinnah Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.